Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7852W HIGH $25.00
Volume
5.45 M
Value Traded
76.26 M
Short % Float
9.48%
Days to Cover
1.2
+0.36%Week
+0.29%1 Month
+77.55%3 Month
+444.75%6 Month
-24.93%5 Year
-24.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.00 B
EPS (TTM)
-1.50
P/E Ratio
-
Ent. Value
822.04 M
Total Shares
71.71 M
Float Shares
51.27 M
Insiders
12.90%
Institutions
75.92%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VTYX Catalyst Timeline
Dated clinical, regulatory and corporate events for Ventyx Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How VTYX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | VTX2735 | Phase 2 interim results | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VTX2735 Small moleculeNCT06836232 | Recurrent Pericarditis | Phase 2 | RECRUITING | 50 | Oct 1, 2027 | ||||||
| VTX3232 Small moleculeCompletedNCT06771115 | Obesity | Phase 2 | COMPLETED | 175 | Sep 10, 2025 | ||||||
| VTX3232 Small moleculeCompletedNCT06556173 | Idiopathic Parkinson Disease | Phase 2 | COMPLETED | 11 | Apr 4, 2025 | ||||||
| VTX2735 Small moleculeCompletedNCT05812781 | Cryopyrin Associated Periodic Syndrome | Phase 2 | COMPLETED | 7 | Mar 6, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every VTYX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VTX3232 | Obesity and Cardiovascular Risk Factors | Phase 2 | 2025-10-22 | 78% reduction in hsCRP at week 12 relative to baseline; 64% reduction in hsCRP at week 12 relative to baseline; statistically significant reductions in IL-6 (p<0.0001); restored nearly 70% of study participants to target hsCRP levels of less than 2mg/LRead More | Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk FactorsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mohan RajuDirector, Officer (CEO AND PRESIDENT) | Sell | -47,345 2,372,863 held | $7.72 | 12/18/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in VTYX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 3.3 % (200 %) | 58.56 M | 6.48 M | 65.24% ( 2.56 M) |
Ownership Trends
VTYX Short Interest
Shares sold short, counted twice a month.
9.48%
Short % of Float
of tradable shares sold short
4.9M
Shares Sold Short
+8.4% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
3.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VTYX ranks across every disease it competes in
Competitive Position is a premium feature
See how VTYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVTYX News
About Ventyx Biosciences, Inc.
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next VTYX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime